Cutaneous Reactions in Pediatric Patients Treated with MEK Inhibitors: A Retrospective Single-Center Study

Keyphrases

• Pediatric Patients 100%
• MEK Inhibitor (MEKi) 100%
• Single-center Study 100%
• Cutaneous Adverse Drug Reactions (cADRs) 100%
• Cutaneous Reaction 100%
• Adverse Events 66%
• Trametinib 66%
• Adverse Effects 33%
• High Prevalence 33%
• Extracellular Signal-regulated Kinase 33%
• Clinical Spectrum 33%
• Pediatric Population 33%
• Dermatologist 33%
• Treatment Facilities 33%
• Collaborative Care 33%
• Dermatitis 33%
• Tertiary Treatment 33%
• Paronychia 33%
• Xerosis 33%
• Dermatology Clinic 33%
• Mitogen-activated 33%
• Proto-oncogene Proteins B-raf 33%
• Dabrafenib 33%
• Selumetinib 33%
• Dermatology Consultation 33%
• Serine-threonine Kinase Inhibitor 33%
• Cutaneous Toxicity 33%
• Hair Heterochromia 33%

Medicine and Dentistry

• Pediatrics Patient 100%
• Adverse Event 100%
• Skin Manifestation 100%
• MEK Inhibitor 100%
• Trametinib 50%
• Adverse Effect 50%
• Prevalence 25%
• Pediatrics 25%
• Dermatology 25%
• Mitogenic Agent 25%
• Casein Kinase 25%
• Proto Oncogene 25%
• Mitogen-Activated Protein Kinase 25%
• Dermatitis 25%
• Paronychia 25%
• Xerosis 25%
• Skin Toxicity 25%
• Dabrafenib 25%
• Selumetinib 25%
• Protein Kinase Inhibitor 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Mitogen Activated Protein Kinase Kinase Inhibitor 100%
• Adverse Event 100%
• Skin Manifestation 100%
• Trametinib 50%
• Prevalence 25%
• Mitogen Activated Protein Kinase 25%
• Mitogenic Agent 25%
• Casein Kinase 25%
• Dermatitis 25%
• Paronychia 25%
• Xerosis 25%
• Skin Toxicity 25%
• Dabrafenib 25%
• Selumetinib 25%
• Protein Kinase Inhibitor 25%